Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,651,579
  • Shares Outstanding, K 101,091
  • Annual Sales, $ 351,320 K
  • Annual Income, $ -7,230 K
  • 60-Month Beta 1.62
  • Price/Sales 21.91
  • Price/Cash Flow N/A
  • Price/Book 28.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.05
  • Number of Estimates 5
  • High Estimate 0.14
  • Low Estimate 0.01
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.02 +28.24%
on 07/15/20
79.73 -5.07%
on 08/07/20
+17.55 (+30.19%)
since 07/14/20
3-Month
55.40 +36.62%
on 07/14/20
79.73 -5.07%
on 08/07/20
+13.62 (+21.94%)
since 05/14/20
52-Week
53.40 +41.74%
on 03/23/20
98.84 -23.42%
on 01/22/20
-10.68 (-12.37%)
since 08/14/19

Most Recent Stories

More News
Novocure Announces Expansion of Its Executive Leadership Team

--Ashley Cordova promoted to Chief Financial Officer

NVCR : 75.69 (-0.58%)
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update

--Financial strength allows for continued investments in clinical and product innovation

NVCR : 75.69 (-0.58%)
Stocks Slide as Tech Stalls Again

Stocks Slide as Tech Stalls Again

BGS : 29.17 (-0.38%)
NTGR : 32.61 (-0.76%)
TPB : 28.80 (-1.81%)
CSPR : 8.17 (-6.09%)
STKL : 6.78 (+1.35%)
LVS : 48.37 (-0.51%)
INCY : 94.87 (-0.72%)
ADSW : 30.20 (unch)
NEO : 38.93 (-3.33%)
MIME : 45.09 (-1.74%)
MPC : 38.35 (+2.93%)
NVCR : 75.69 (-0.58%)
MTCH : 118.80 (+1.16%)
RUN : 45.63 (-2.35%)
TJX : 57.87 (+1.33%)
TIF : 125.00 (+0.16%)
VFC : 64.24 (+0.64%)
XYL : 79.62 (+0.18%)
YNDX : 60.04 (+0.92%)
GOOG : 1,507.73 (-0.71%)
AMZN : 3,148.02 (-0.41%)
AAPL : 459.63 (-0.09%)
PFE : 38.06 (-0.29%)
MMM : 166.10 (+0.14%)
MCD : 207.03 (+0.26%)
AMD : 81.30 (-0.66%)
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American Association...

NVCR : 75.69 (-0.58%)
First Patient Enrolled in Novocure's EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays

Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent...

NVCR : 75.69 (-0.58%)
Sophisticated Medical Devices Allow for Improved Patient Monitoring

, /PRNewswire/ -- Medical devices range from simple tongue depressors and bedpans to complex programmable pacemakers and closed loop artificial pancreas systems. In addition, in vitro diagnostic (IVD)...

NMRD : 5.54 (-2.46%)
NVCR : 75.69 (-0.58%)
RMD : 176.78 (-0.41%)
BSX : 39.16 (-1.48%)
IRTC : 172.95 (-2.96%)
Novocure Announces Launch of MyLink(TM) to Enable Patient-Guided, Remote Download of Optune(R) Usage Data

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure...

NVCR : 75.69 (-0.58%)
China NMPA Approves Optune(R) for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

--A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate(1)

NVCR : 75.69 (-0.58%)
ZLAB : 79.53 (-2.17%)
China NMPA Approves Optune(R) for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years

NVCR : 75.69 (-0.58%)
ZLAB : 79.53 (-2.17%)
NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 75.69 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 76.63
1st Resistance Point 76.16
Last Price 75.69
1st Support Level 75.15
2nd Support Level 74.61

See More

52-Week High 98.84
Fibonacci 61.8% 81.48
Fibonacci 50% 76.12
Last Price 75.69
Fibonacci 38.2% 70.76
52-Week Low 53.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar